Doctors Urge Caution In Interpreting FDA’s SGLT2 Warning
Executive Summary
Endocrinologists raise concerns over FDA case reports because diabetic ketoacidosis may be a risk for type 1 diabetes patients taking SGLT2 inhibitors, but it is very rare in type 2 diabetes.